GM-CSF in neuroinflammation: licensing myeloid cells for tissue damage

AL Croxford, S Spath, B Becher - Trends in immunology, 2015 - cell.com
AL Croxford, S Spath, B Becher
Trends in immunology, 2015cell.com
Multiple sclerosis (MS) is the prototypical inflammatory disease of the central nervous
system (CNS). MS lesions harbor different immune cells, but the contribution of individual
cell types to disease etiology and progression is not well understood. In experimental
autoimmune encephalomyelitis (EAE), auto-reactive helper T (Th) cells instigate CNS
inflammation by acting on myeloid cells via the production of granulocyte-macrophage
colony-stimulating factor (GM-CSF). Recent reports have implicated myeloid cells in both the …
Multiple sclerosis (MS) is the prototypical inflammatory disease of the central nervous system (CNS). MS lesions harbor different immune cells, but the contribution of individual cell types to disease etiology and progression is not well understood. In experimental autoimmune encephalomyelitis (EAE), auto-reactive helper T (Th) cells instigate CNS inflammation by acting on myeloid cells via the production of granulocyte-macrophage colony-stimulating factor (GM-CSF). Recent reports have implicated myeloid cells in both the inflammatory process and as executers of tissue damage in the CNS. We review these findings here, and integrate them into a model wherein GM-CSF produced by Th cells coordinates monocyte recruitment to the CNS, and differentiation into pathogenic effectors. We discuss the implications of this model to current therapies for MS, and outline important areas of further inquiry.
cell.com